Production (Stage)
Castle Biosciences, Inc.
CSTL
$16.10
$0.211.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 38.43% | 51.09% | 62.43% | 71.67% | 64.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.43% | 51.09% | 62.43% | 71.67% | 64.71% |
| Cost of Revenue | 28.75% | 33.84% | 34.14% | 31.64% | 34.34% |
| Gross Profit | 40.77% | 55.52% | 70.37% | 84.07% | 74.20% |
| SG&A Expenses | 15.55% | 11.04% | 11.28% | 13.09% | 15.41% |
| Depreciation & Amortization | 311.42% | 23.22% | 0.89% | 0.51% | 2.24% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.31% | 12.38% | 12.78% | 14.46% | 16.49% |
| Operating Income | 67.12% | 112.75% | 98.79% | 83.84% | 57.65% |
| Income Before Tax | 92.77% | 137.59% | 114.77% | 95.47% | 58.34% |
| Income Tax Expenses | 2,059.85% | 3,186.14% | 4,154.62% | -1,155.17% | 107.00% |
| Earnings from Continuing Operations | 83.54% | 131.75% | 108.05% | 96.51% | 57.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.54% | 131.75% | 108.05% | 96.51% | 57.06% |
| EBIT | 67.12% | 112.75% | 98.79% | 83.84% | 57.65% |
| EBITDA | 198.24% | 144.33% | 116.89% | 96.89% | 66.77% |
| EPS Basic | 86.20% | 130.33% | 107.63% | 96.35% | 57.68% |
| Normalized Basic EPS | 97.80% | 135.03% | 113.99% | 95.38% | 67.52% |
| EPS Diluted | 82.66% | 128.36% | 107.12% | 95.90% | 57.62% |
| Normalized Diluted EPS | 93.91% | 132.96% | 113.06% | 95.05% | 67.52% |
| Average Basic Shares Outstanding | 3.83% | 3.63% | 3.22% | 2.77% | 2.56% |
| Average Diluted Shares Outstanding | 8.20% | 8.04% | 5.70% | 3.80% | 2.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |